e6742

E6742 is a novel, first-in-class, orally available small molecule inhibitor that selectively antagonizes toll-like receptors 7 and 8 (TLR7/8). By binding to the hydrophobic pocket of the inactive form of TLR7 and TLR8 dimers, E6742 blocks their activation, thereby suppressing downstream cytokine responses implicated in autoimmune diseases such as systemic lupus erythematosus (SLE)[1][2][5][7]. Preclinical studies demonstrated that E6742 can ameliorate disease parameters in murine models of lupus and may have glucocorticoid-sparing potential[1][2][7]. Clinical trials have shown favorable safety, tolerability, pharmacokinetics, biomarker response (notably suppression of interferon gene signature), and preliminary efficacy signals in patients with SLE[1][3]. The drug is being developed by Eisai for the treatment of SLE[4].